Loading stock data…
$4.27-0.20 (-4.58%)
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs).
Coya Therapeutics, Inc. in the Healthcare sector is trading at $4.29 with a market capitalization of $101M. Wall Street consensus targets $15.21 (7 analysts), implying a +254.6% move over the next 12 months. The stock is currently near its 52-week low of $3.71, remaining 8.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $243,745↓ | $251,147↓ | $3.96M↑ | $3.56M↑ | $163,616 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.05M↑ | -$7.64M↓ | -$6.03M↓ | -$2.43M↑ | -$6.41M |
| Net Income | -$6.64M↑ | -$7.21M↓ | -$5.71M↓ | -$2.12M↑ | -$6.09M |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Tre...